Document Detail

The SSG XVIII/AIO Trial: Results Change the Current Adjuvant Treatment Recommendations for Gastrointestinal Stromal Tumors.
MedLine Citation:
PMID:  23334483     Owner:  NLM     Status:  In-Data-Review    
Although adjuvant imatinib (IM) for high risk GIST is an accepted treatment consideration, the duration of therapy remains controversial. The recently published SSGXVIII/AIO randomized clinical trial of 3 years vs. 1 year of adjuvant IM has established a benefit of RFS and OS for the 3 year cohort. Future studies are necessary to continue to further delineate risk variables for GIST recurrence.
Burton L Eisenberg
Related Documents :
24297953 - Fractionated 90y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of folli...
24552893 - Study of biomolecular and clinical prognostic factors in patients with cancer of the vu...
9414403 - A phase ii trial of paclitaxel in the treatment of recurrent or metastatic soft tissue ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  36     ISSN:  1537-453X     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  89-90     Citation Subset:  IM    
Department of Surgery, Section of Surgical Oncology, Geisel School of Medicine at Dartmouth Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, LH.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Toxicity assessment of anaerobic digestion intermediates and antibiotics in pharmaceutical wastewate...
Next Document:  American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Gui...